Search

Your search keyword '"Barnabas, Shaun L."' showing total 142 results

Search Constraints

Start Over You searched for: Author "Barnabas, Shaun L." Remove constraint Author: "Barnabas, Shaun L."
142 results on '"Barnabas, Shaun L."'

Search Results

1. Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries

2. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19

3. Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial.

4. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study

5. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

7. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.

8. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

9. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

10. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

11. Early Proteomic and Innate Immunity Profiles: A Footprint of Increased Mortality Risk In Infants Living with Hiv From Three African Countries

14. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

16. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

17. Associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school‐age children: a two‐way factorial case–control study

18. Efficacy of Primary Series AZD1222 (ChAdOx1 nCoV-19) Vaccination Against SARS-CoV-2 Variants of Concern: Final Analysis of a Randomized, Placebo-controlled, Phase 1b/2 Study in South African Adults (COV005)

19. High Mortality Following Early Initiation of Antiretroviral Therapy in Infants Living with HIV from Three African Countries

23. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

24. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

25. Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern

26. Systems Analysis Reveals Contraceptive-Induced Alteration of Cervicovaginal Gene Expression in a Randomized Trial

27. Anaemia, iron and vitamin A status among South African school-aged children living with and without HIV

28. Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial

29. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

30. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

31. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

33. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

34. Hormonal contraception and risk of STIs and bacterial vaginosis in South African adolescents: secondary analysis of a randomised trial

35. Relationship between the Oral and Vaginal Microbiota of South African Adolescents with High Prevalence of Bacterial Vaginosis

36. Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis

37. Results from the first South African Health Products Regulatory Authority-approved randomised trial evaluating supplementation of standard antibiotic therapy with a commercially available probiotic in South African women with bacterial vaginosis

38. Additional file 1 of Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis

39. Geografiese ligging beïnvloed vaginale mikrobiese profiele in Suid-Afrikaanse vroue

41. Defining characteristics of genital health in South African adolescent girls and young women at high risk for HIV infection

42. Hormonal contraception and risk of STIs and bacterial vaginosis in South African adolescents: secondary analysis of a randomised trial.

43. Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females

44. High rates of bacterial vaginosis and Chlamydia in a low-income, high-population-density community in Cape Town

45. Hoë voorkomskoers van bakteriële vaginose en Chlamydia in ’n lae-inkomste, hoë-bevolkingsdigtheid gemeenskap in Kaapstad

47. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV.

48. Impact of Persistent Human Papillomavirus (HPV) Infections on Inflammatory Cytokine Levels in the Female Genital Tract: Implications for HIV Risk

49. Immune Activation and HIV Target Cells in the Adolescent Female Genital Tract

50. High rates of bacterial vaginosis and Chlamydia in a low-income, high-population-density community in Cape Town.

Catalog

Books, media, physical & digital resources